A pooled analysis of data from @,@ patients in @ phase II trials assessed the effects of evolocumab , a fully human monoclonal antibody to PCSK@ , on Lp ( a ) , the relationship between Lp ( a ) and lowering of low-density lipoprotein cholesterol ( LDL-C ) and apolipoprotein B , and the influence of background statin therapy .